EA202091120A3 - Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы - Google Patents
Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системыInfo
- Publication number
- EA202091120A3 EA202091120A3 EA202091120A EA202091120A EA202091120A3 EA 202091120 A3 EA202091120 A3 EA 202091120A3 EA 202091120 A EA202091120 A EA 202091120A EA 202091120 A EA202091120 A EA 202091120A EA 202091120 A3 EA202091120 A3 EA 202091120A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- nervous system
- central nervous
- disorders
- thiazolinidone
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA202091120A2 EA202091120A2 (ru) | 2020-08-31 |
| EA202091120A3 true EA202091120A3 (ru) | 2020-12-30 |
Family
ID=50513194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091120A EA202091120A3 (ru) | 2014-04-02 | 2015-04-01 | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы |
| EA201691997A EA035866B1 (ru) | 2014-04-02 | 2015-04-01 | Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691997A EA035866B1 (ru) | 2014-04-02 | 2015-04-01 | Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9782395B2 (https=) |
| EP (2) | EP3125888B1 (https=) |
| JP (2) | JP6745726B2 (https=) |
| KR (1) | KR102418167B1 (https=) |
| CN (1) | CN106470991B (https=) |
| AU (1) | AU2015239112C1 (https=) |
| CA (1) | CA2943373C (https=) |
| CL (1) | CL2016002508A1 (https=) |
| CY (2) | CY1120454T1 (https=) |
| DK (2) | DK3388064T3 (https=) |
| EA (2) | EA202091120A3 (https=) |
| ES (2) | ES2872335T3 (https=) |
| HR (2) | HRP20180983T1 (https=) |
| HU (2) | HUE055351T2 (https=) |
| IL (1) | IL248037B (https=) |
| LT (2) | LT3125888T (https=) |
| MX (1) | MX373234B (https=) |
| NZ (1) | NZ725492A (https=) |
| PL (2) | PL3125888T3 (https=) |
| PT (2) | PT3125888T (https=) |
| SG (1) | SG11201608218QA (https=) |
| SI (2) | SI3125888T1 (https=) |
| WO (1) | WO2015150476A1 (https=) |
| ZA (1) | ZA201607286B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CA2941562C (en) * | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EP3125888B1 (en) * | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| EP3548026B1 (en) * | 2016-12-01 | 2021-01-20 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| EP3559010B1 (en) * | 2016-12-23 | 2022-06-08 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
| EA202092954A1 (ru) | 2018-06-06 | 2021-04-08 | Минорикс Терапьютикс С.Л. | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей |
| FI3801515T3 (fi) | 2018-06-06 | 2025-05-27 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa |
| BR112020024917A2 (pt) * | 2018-06-06 | 2021-03-09 | Minoryx Therapeutics S.L. | Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona |
| EP4142720A1 (en) | 2020-04-30 | 2023-03-08 | Minoryx Therapeutics S.L. | Leriglitazone for treating lung inflammation and interstitial lung disease |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| MX2025013233A (es) | 2023-05-09 | 2026-02-03 | Minoryx Therapeutics S L | Formas polimorficas y formulaciones de leriglitazona |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2106967C (en) * | 1991-04-11 | 2003-12-09 | Takashi Sohda | Thiazolidinedione derivatives, production and use thereof |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| AU4104593A (en) * | 1992-05-05 | 1993-11-29 | Upjohn Company, The | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| AU2002367154A1 (en) | 2001-12-21 | 2003-07-15 | Smithkline Beecham Corporation | Dosing regimen for ppar-gamma activators |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| AU2003254146A1 (en) * | 2003-07-24 | 2005-03-07 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| UA96441C2 (ru) | 2006-03-16 | 2011-11-10 | Метаболик Солюшнз Девелопмент Компани | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| ES2617704T3 (es) * | 2009-12-15 | 2017-06-19 | Octeta Therapeutics, Llc | Tiazolidindionas ahorradoras de PPAR y combinaciones para el tratamiento de enfermedades neurodegenerativas |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EP3125888B1 (en) * | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
-
2015
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/da active
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/lt unknown
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 ES ES18173541T patent/ES2872335T3/es active Active
- 2015-04-01 PL PL15713499T patent/PL3125888T3/pl unknown
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/hu unknown
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en not_active Ceased
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 EA EA202091120A patent/EA202091120A3/ru unknown
- 2015-04-01 PT PT157134990T patent/PT3125888T/pt unknown
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/hu unknown
- 2015-04-01 EA EA201691997A patent/EA035866B1/ru unknown
- 2015-04-01 MX MX2016012687A patent/MX373234B/es active IP Right Grant
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 PL PL18173541T patent/PL3388064T3/pl unknown
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/ko active Active
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/zh active Active
- 2015-04-01 HR HRP20180983TT patent/HRP20180983T1/hr unknown
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/es active Active
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/ja active Active
- 2015-04-01 PT PT181735416T patent/PT3388064T/pt unknown
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/lt unknown
- 2015-04-01 SI SI201531591T patent/SI3388064T1/sl unknown
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
-
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/es unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
-
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
-
2018
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/el unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/ja active Pending
-
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/hr unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091120A2 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| MX2015013481A (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
| EA202092442A3 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| PE20161438A1 (es) | Inhibidores de desmetilasa 1 especifica a lisina | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| HUE042840T2 (hu) | 5-[(Piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-dion-származékok mint csontartritisz kezelésére alkalmas ADAMTS inhibitorok | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EA201791030A1 (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| UY37517A (es) | Métodos de síntesis de compuestos tiazoles sustituidos | |
| EA201790206A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4 | |
| MX390051B (es) | Antagonistas de ep4. | |
| EA201692474A1 (ru) | Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2 | |
| EA201790209A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde | |
| IL257422A (en) | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| NZ630803A (en) | Optically active pde10 inhibitor |